

Erratum to: Management of transthyretin amyloidosis

Erratum to Swiss Med Wkly. 2021;151:w30053 (DOI 10.4414/smw.2021.w30053)

The published manuscript contained a typing error in the chapter "Wild-type transthyretin amyloidosis (ATTRwt)", subchapter "Treatment" (page 13 of the PDF version). It reads: *Treatment with tafamidis 61 mg should be considered for patients with cardiac ATTRwt amyloidosis and dyspnea NYHA I-II. [IIa, B].*

The correct wording is: *Treatment with tafamidis 61 mg should be considered for patients with cardiac ATTRwt amyloidosis and dyspnea NYHA I-III. [IIa, B].*

The error occurred during manuscript editing and is not in the authors' responsibility. It has now been corrected online. We apologize to the authors and readers for this error.